Saxagliptin: all 94 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)RecruitingNCT02969798Not applicable
• To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus PatientsCompletedNCT04445714Phase 4Results posted
• Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years OldCompletedNCT03199053Phase 3Results posted
• Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart FailureCompletedNCT02917031Phase 4Results posted
• A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 DiabetesCompletedNCT02681094Phase 3Results posted
• ESR-15-11293 - Saxa/Dapa, Safety and Efficacy StudyCompletedNCT02613897Not applicableResults posted
• A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKDCompletedNCT02547935Phase 2/3Results posted
• Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With SulphonylureaCompletedNCT02471404Phase 4Results posted
• A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin AloneCompletedNCT02419612Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy AloneCompletedNCT02284893Phase 3Results posted
• Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic ControlCompletedNCT02273050Phase 3Results posted
• 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin MonotherapyCompletedNCT02243176Phase 4Results posted
• Bioequivalence Study Coadministered to Healthy Subjects in the Fasted StateCompletedNCT02223065Phase 1Results posted
• Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized PatientCompletedNCT02182895Phase 4Results posted
• Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic ControlCompletedNCT02104804Phase 3Results posted
• Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM PatientsCompletedNCT02024477Phase 4Results posted
• Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft SurgeryTerminatedNCT01765270Phase 4Results posted
• Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy ParticipantsCompletedNCT01662999Phase 1Results posted
• Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 DiabetesCompletedNCT01619059Phase 3Results posted
• The Efficacy and Safety Study in Patients With Type 2 Diabetes MellitusCompletedNCT01608724Phase 4Results posted
• Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 DiabetesCompletedNCT01606007Phase 3Results posted
• A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)CompletedNCT01582308Phase 1Results posted
• Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte InflammationTerminatedNCT01548651Phase 4Results posted
• Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DMTerminatedNCT01525225Phase 1Results posted
• A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin AloneCompletedNCT01434186Phase 3Results posted
• Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-BrazilCompletedNCT01365091Phase 1Results posted
• Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 DiabetesCompletedNCT01204775Phase 3Results posted
• Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XRCompletedNCT01192152Phase 1Results posted
• Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)CompletedNCT01192139Phase 1Results posted
• Saxagliptin Triple Oral TherapyCompletedNCT01128153Phase 3Results posted
• Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes MedicationsCompletedNCT01107886Phase 4Results posted
• Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-AdministeredCompletedNCT01068743Phase 1Results posted
• Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy ParticipantsCompletedNCT01068717Phase 1Results posted
• Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on MetforminCompletedNCT01006603Phase 4Results posted
• Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 DiabetesCompletedNCT01006590Phase 4Results posted
• An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 DiabetesCompletedNCT00960076Phase 3Results posted
• Study of Multiple Doses of Saxagliptin (BMS-477118)CompletedNCT00950599Phase 2Results posted
• Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic ControlCompletedNCT00918879Phase 3Results posted
• Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mgCompletedNCT00918138Phase 3Results posted
• Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)CompletedNCT00899470Phase 1Results posted
• Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)CompletedNCT00897390Phase 1Results posted
• Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes MellitusCompletedNCT00885378Phase 3Results posted
• Safety and Efficacy of Saxagliptin Plus Insulin With or Without MetforminCompletedNCT00757588Phase 3Results posted
• Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic ControlCompletedNCT00698932Phase 3Results posted
• Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR AloneCompletedNCT00683657Phase 3Results posted
• 18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)CompletedNCT00666458Phase 3Results posted
• Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 DiabetesCompletedNCT00661362Phase 3Results posted
• Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal ImpairmentCompletedNCT00614939Phase 3Results posted
• 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension PeriodCompletedNCT00575588Phase 3Results posted
• A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedNCT00374907Phase 3Results posted
• A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedNCT00327015Phase 3Results posted
• Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedNCT00316082Phase 3Results posted
• A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With SulfonylureasCompletedNCT00313313Phase 3Results posted
• A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy AloneCompletedNCT00295633Phase 3Results posted
• Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin AloneCompletedNCT00121667Phase 3Results posted
• Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedNCT00121641Phase 3Results posted
• Tubular Markers in Response to Saxagliptin TherapyCompletedNCT04521049Phase 4
• Evaluation of Drug Interactions of Saxagliptin With Sildenafil in Healthy VolunteersStatus unknownNCT04170790Not applicable
• Neuropeptide Y and Sympathovagal BalanceCompletedNCT03933787Early Phase 1
• Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.CompletedNCT03714594Phase 2
• A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.CompletedNCT03169959Phase 1
• Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic PatientsCompletedNCT02920801Phase 4
• Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic UlcersStatus unknownNCT02742233Phase 4
• Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 DiabetesStatus unknownNCT02583438Phase 4
• Saxagliptin and Cardiac Structure and FunctionCompletedNCT02481479Phase 4
• Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic PatientsStatus unknownNCT02462369Phase 4
• Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune DiabetesCompletedNCT02407899Phase 4
• Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic ClampStatus unknownNCT02386943Phase 4
• Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 DiabetesCompletedNCT02315495Phase 3
• The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 DiabetesStatus unknownNCT02307695Phase 4
• Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell FunctionCompletedNCT02304081Phase 4
• Effects of Saxagliptin on Adipose Tissue Inflammation in HumansCompletedNCT02285985Phase 4
• Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With MetforminCompletedNCT02280486Phase 4
• DPP-IV Inhibition Prior to Development of Diabetes in Patients With Cystic FibrosisStatus unknownNCT02239458Not applicable
• Cystic Fibrosis Related DiabetesStatus unknownNCT02148978Not applicable
• DPP-4 Inhibition, Incretins and Islet FunctionCompletedNCT02089438Phase 4
• Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)CompletedNCT02060201Phase 1
• Effect of Saxagliptin on Pre-Diabetes Mellitus and ObesityStatus unknownNCT01960205Phase 4
• DPP4inhibitors in Type 1 DiabetesCompletedNCT01922817Phase 3
• Bioequivalence StudyCompletedNCT01874080Phase 1
• Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus PatientsStatus unknownNCT01768208Phase 4
• Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and SaxagliptinStatus unknownNCT01703637Not applicable
• Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp"Status unknownNCT01660386Phase 4
• Saxagliptin and AtherosclerosisCompletedNCT01552018Phase 4
• Effects of DPP-4 Inhibition on TriglyceridesSuspendedNCT01527747Phase 4
• ACute and Chronic Effects of SaxagliptinCompletedNCT01521312Phase 2
• Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin ProducCompletedNCT01441869Phase 1
• Effects of Saxagliptin on Endothelial FunctionCompletedNCT01319357Phase 3
• BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed StatesWithdrawnNCT01305551Phase 1
• Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe HyperglycemiaCompletedNCT01267448Phase 4
• Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes MellitusStatus unknownNCT01206647Phase 4
• Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy SubjectsCompletedNCT00935467Phase 1
• A Phase 2 Study of OPC-262 in Patients With Type 2 DiabetesCompletedNCT00857558Phase 2
• Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of SaxagliptinCompletedNCT00770302Phase 1

← Saxagliptin overview